This clinical trial is for men and women age 18 and older with B-cell non-follicular indolent non-Hodgkin’s lymphoma. Relapsed and refractory indolent non-Hodgkin’s lymphomas are difficult to treat with poor overall response rate and overall survival.
TGR-1202 (Umbralisib) is a highly-specific phosphoinositide-3-kinase (PI3K) delta inhibitor with nanomolar inhibitory potency, and high selectivity over the alpha, beta, and gamma isoforms. The delta isoform of PI3K is believed to be important in the proliferation and survival of B-cell lymphocytes.
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in previously treated non-follicular indolent non-Hodgkin’s lymphoma patients.